Indian Pharma

Lupin gains 2%, hits 52-week high; why pharma stock in focus?

Lupin management remains confident that the India formulations business will continue to outperform IPM by 1.2-1.3 times, supported by strong sales force and pipeline of new product launches.

AI, trust and faster innovation bets to shape India's pharma future by 2047

At the IPA summit, pharma leaders said India's 2047 ambitions depend on embedding AI, strengthening trust and accelerating innovation, as speed and quality become the sector's defining advantages

India's drugmakers show fewer side effects under harsher USFDA scrutiny

USFDA data show OAI rates for Indian pharma plants falling to 8% by 2025 even as global outcomes worsen, reflecting stronger quality systems, technology adoption and compliance culture

Indian pharma may face muted US growth in FY27 on gRevlimid pressure

Ind-Ra says Indian drugmakers will still see 10% revenue growth in FY27 driven by domestic demand and CDMO traction, despite weaker US sales after Revlimid expiry

US-Bangladesh pact unlikely to impact India's pharma, medtech exports

Industry executives say the US-Bangladesh reciprocal trade agreement is unlikely to materially affect India's pharma and medtech exports, given India's scale and established FDA-approved supply chains

Indian Pharmacopoeia Commission signs 3 MoUs to strengthen drug safety

The Indian Pharmacopoeia Commission (IPC) has signed memoranda of understanding with the Goa State Pharmacy Council, Quality Council of India, and HLL Infra Tech Services Limited, to strengthen drug safety, quality assurance, and capacity-building initiatives. The IPC, an autonomous body under the Health Ministry, has been making efforts to foster institutional partnerships with regulatory bodies, professional councils, quality organisations, and public sector enterprises to strengthen pharmacovigilance systems, enhance professional competencies, and promote uniform standards for medicine quality and patient safety across India. The memorandum of understanding (MoU) signed between IPC and Goa State Pharmacy Council (GSPC) provides a structured framework for collaboration in pharmacovigilance, rational use of medicines, and professional development of pharmacists in the state, the health ministry said in a statement. It envisages promotion of the National Formulary of India among ...

Non-animal testing can cut drug costs by up to 90%, says report

Dr Reddy's, Biocon and Sun Pharma are exploring human-based testing methods that could halve drug development timelines and sharply reduce costs, while meeting global regulatory standards

FM announces ₹10,000 crore scheme to promote biopharma manufacturing

Finance Minister Nirmala Sitharaman announced Mission Biopharma Shakti in the Budget, a five-year ₹10,000 crore programme to build domestic capabilities in biologics, biosimilars and clinical research

India-EU FTA: Indian pharma to get stronger dose of EU market access

EU's zero-tariff offer on most chemical and medical exports is set to boost India's pharma, medtech and biosimilars access to European markets

Antimicrobial sales growth set to temper in 2026 over govt's AMR push

Stricter rules to curb antimicrobial resistance may limit antibiotic sales growth in 2026, as India tightens OTC use and pushes prescription-led, responsible consumption

Sai Life rallies 5%, hits all-time high; what's driving pharma stock?

In H1FY26, total revenue of the Sai Life Sciences increased by 53% YoY at ₹1,034 crore, driven by healthy growth across both the CRO and the CDMO business.

Semaglutide patent loss to create ₹5,000 crore opportunity: Report

Patent expiries of blockbuster weight-loss drug semaglutide may create a ₹5,000 crore generic opportunity for Indian pharma firms across India and key emerging and regulated markets

Indian pharma companies see sharp drop in adverse USFDA findings in 2025

OAI cases nearly halve in 2025, overall inspection volumes also fell 25%

Pharma leaders flag quality, sustainability as export priorities for 2026

At Pharmexcil's 2025 AGM, industry leaders stressed a shift from volume-led growth to quality, sustainability and market diversification as India's pharma export strategy looks ahead to 2026

'Eye on $500 bn by 2047, pharma steps into 2026 with focus on innovation'

India's pharmaceutical industry is stepping into 2026, marking the beginning of a critical five-year period to build the required ecosystem to establish itself as an innovation hub in its bid to become a USD 500 billion sector by 2047, amid near-term challenges of tariff fluctuations and global trade realignments. The predominantly generic medicines-driven domestic drug industry, which has grown from USD 3 billion to USD 60 billion in size over the past 25 years, is shifting towards innovation in next-generation drugs. At the same time, it will also seek to capitalise on the opportunity to capture drugs worth over USD 300 billion that are set to lose exclusivity over the next seven years. "Today, Indian pharma stands at a defining moment and the next 25 years will be shaped by innovation, quality, and access," Indian Pharmaceutical Alliance Secretary General Sudarshan Jain said. The innovation agenda has gained notable momentum among the domestic players, he noted. "From 2026 onwa

USFDA's new biosimilar norms to woo more players, fast-track mkt entry

Indian cos like Biocon, DRL, Intas, Lupin stand to benefit from the proposed move

Death in a bottle: Toxic cough syrups once again prove fatal for children

Toxic cough syrups have once again proven fatal for children. This time, the tragedy has happened in India. Here's a look at why this sordid tale never seems to let up

Pharma market grows 8.7% in August; cardiac and anti-diabetic segments lead

The Indian Pharma Market grew 8.7% in August 2025, with the cardiac, anti-diabetic, and anti-neoplastic segments driving growth. Sun Pharma maintained its leadership position

Tariffs, costs, and shifting strategies: Indian pharma's new playbook

Analysts say Indian pharma firms will increase focus on non-US exports and the domestic market as US tariff threats persist, with firms exploring offshore manufacturing options

US pharma tariffs unlikely to hit Indian drugmakers materially: Ind-Ra

Ind-Ra said US tariffs may cause only short-term pricing impact for Indian pharma as firms remain fortified by diversification, strong balance sheets, and global market positioning